Prostate Cancer Trial, Recruiting (NCT05710380)

Prostate Cancer Trial, Recruiting NCT05710380 Sponsor: University of Chicago Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05710380 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People with known or suspected prostate cancer who have been referred for a prostate MRI scan, to be followed by a type of biopsy that uses MRI imaging as a guide.
People who are willing and able to give written consent to take part before the MRI scan takes place.

Who may not be able to join:

People who are not able to give written consent for themselves.
People who are unable to follow the study procedures for any reason, or who are unable to communicate with the research team.
People whose psychiatric condition affects their ability to make their own decision about consenting to take part (note: this applies only where the ability to consent is affected, not to all people with a psychiatric condition).
People who are currently in prison.
People under the age of 18.
People who have already received treatment for prostate cancer, such as surgery, radiation therapy, targeted ablation, hormone therapy, or other chemotherapy.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Aytekin Oto, MD, University of Chicago Medicine Comprehensive Cancer Center

Phone: 773-702-8553

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05710380

Sponsor: University of Chicago

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 773-702-8553

More information: https://clinicaltrials.gov/study/NCT05710380

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People with known or suspected prostate cancer who have been referred for a prostate MRI scan, to be followed by a type of biopsy that uses MRI imaging as a guide.
People who are willing and able to give written consent to take part before the MRI scan takes place.

Who may not be able to join:

People who are not able to give written consent for themselves.
People who are unable to follow the study procedures for any reason, or who are unable to communicate with the research team.
People whose psychiatric condition affects their ability to make their own decision about consenting to take part (note: this applies only where the ability to consent is affected, not to all people with a psychiatric condition).
People who are currently in prison.
People under the age of 18.
People who have already received treatment for prostate cancer, such as surgery, radiation therapy, targeted ablation, hormone therapy, or other chemotherapy.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Chicago

Registry

ClinicalTrials.gov

Start date

26 April 2023

Est. completion

1 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Decision Map Tool Compared to Oncologists

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov